New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.
about
Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.Defining the mechanism of polymerization in the serpinopathies.α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.Therapeutic targeting of misfolding and conformational change in α1-antitrypsin deficiency.Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesisIdentification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolismα(1)-antitrypsin deficiency and inflammation.Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent.Twenty years of polymers: a personal perspective on alpha-1 antitrypsin deficiency.The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.Neutrophilic panniculitis associated with alpha-1-antitrypsin deficiency: an update.Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibodyAn ECLIPSE View of Alpha-1 Antitrypsin Deficiency.Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency.Liquefying panniculitis associated with intraductal papillary mucinous neoplasm.The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals.
P2860
Q33743024-140B0D2E-7C7C-4418-8BE1-01104357F760Q34182669-6F44BF61-2C23-437A-891E-6845021EA5B4Q34428735-6EC43076-94AD-46EB-89AF-8AC6A69C1699Q34980209-B28AF9AF-0855-4BA1-B0BD-499672F75CADQ35214289-A22BCBEB-987C-4FC6-ACD5-14E7DE4BADA1Q35233352-22C1AF04-64FD-429D-8E65-FF964A5D445DQ35596461-6C9DEDFF-08BD-41D9-A59D-580F93D7F5C4Q37855954-C6E077CB-396A-417A-AE00-07A6282F4D4DQ37986292-51CCDA21-1DD1-454D-8B0B-DB7818A6B6D5Q38092851-0937F32F-0B22-4EC4-ACD5-CF3EC6E689F0Q38604630-4F139FEE-781A-4125-9C5F-9AE23A5EDB18Q38643507-F83DA593-7D08-42F5-98F7-FDF5BE6BD4DBQ38933451-3485D725-EE17-47AC-8989-BB6DC261FE11Q38937853-4661DB7B-FA8E-41F8-A192-0D3C3A072039Q38988633-0296A4AB-3C2D-4808-B7ED-DB8EAAF8B856Q42090487-7181884D-8134-4ADE-9BED-952A34F91C04Q55011363-37111640-9268-4246-99E0-40F5F8D7AA09
P2860
New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New Findings in PiZZ alpha1-an ...... ravenous augmentation therapy.
@en
New Findings in PiZZ alpha1-an ...... ravenous augmentation therapy.
@nl
type
label
New Findings in PiZZ alpha1-an ...... ravenous augmentation therapy.
@en
New Findings in PiZZ alpha1-an ...... ravenous augmentation therapy.
@nl
prefLabel
New Findings in PiZZ alpha1-an ...... ravenous augmentation therapy.
@en
New Findings in PiZZ alpha1-an ...... ravenous augmentation therapy.
@nl
P2093
P2860
P356
P1433
P1476
New Findings in PiZZ alpha1-an ...... ravenous augmentation therapy.
@en
P2093
J K Stoller
L M Bjursten
S Janciauskiene
P2860
P304
P356
10.1159/000202982
P577
2009-02-16T00:00:00Z